Xenotransplantation

British Journal of Surgery

Volumn 87, Issue 2, 2000, Pages 138-148

  Soin, B ^c   Vial, C M ^b   Friend, P J ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c John Radcliffe Hospital Headington ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ARTICLE; BABOON; CHIMPANZEE; ENDOTHELIUM CELL; GRAFT REJECTION; GUINEA PIG; HAMSTER; HUMAN; IMMUNE RESPONSE; MEDICAL INFORMATION; MOUSE; NONHUMAN; ORGAN DONOR; PATHOGENESIS; PRIMATE; PRIORITY JOURNAL; RECIPIENT; RISK; SPLENECTOMY; SWINE; XENOTRANSPLANTATION; ZOONOSIS;

ANIMALS; ANTIBODIES; CYCLOPHOSPHAMIDE; FORECASTING; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RESEARCH; RISK FACTORS; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS; ZOONOSES;

EID: 0033967342     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2000.01351.x     Document Type: Article

References (147)

1. 1 Evans R, Orians C, Ascher N. The potential supply of organ donors. An assessment of the efficacy of organ procurement efforts in the United States. Jama 1992; 267: 239-46.
2. 2 Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: fifteenth official report-1998. J Heart Lung Transplant 1998; 17: 656-68.
3. 3 Pierson RN III, Reed GW, Bennett LE, Keck BM, Hosenpud JD. Short-and intermediate-term implications of using older donors for heart transplantation. Transplant Proc 1997; 29: 593-4.
4. 4 Auchincloss HJ Jr, Sachs DH. Xenogeneic transplantation. Annu Rev Immunol 1998; 16: 433-70.
5. 5 Bach FH, Winkler H, Ferran C, Hancock WW, Robson SC. Delayed xenograft rejection. Immunol Today 1996; 17: 379-84.
6. 6 Bach FH. Xenotransplantation: problems and prospects. Annu Rev Med 1998; 49: 301-10.
7. 7 Platt JL. Xenotransplantation: a potential solution to the shortage of donor organs. Transplant Proc 1997; 29: 3324-6.
8. 8 Princeteau M. Greffe Renale. Journal Medicine de Bordeaux 1905; 26: 549-55.
9. 9 Reemtsma K. Renal heterotransplantation from nonhuman primates to man. Ann NY Acad Sci 1969; 162: 412-18.
10. 10 Starzl TE, FungJ, Tzakis A, Todo S, Demetris AJ, Marino IR et al. Baboon-to-human liver transplantation. Lancet 1993; 341: 65-71.
11. 11 Bailey LL, Nehlsen-Cannarella SL, Concepcion W, Jolley WB. Baboon-to-human cardiac xenotransplantation in a neonate. JAMA 1985; 254: 3321-9.
12. 12 Kawauchi M, Gundry SR, de Begona JA, Razzouk AJ, Bouchart F, Fukushima N et al. Prolonged survival of orthotopically transplanted heart xenograft in infant baboons. J Thorac Cardiovasc Surg 1993; 106: 779-86.
13. 13 Deacon T, Schumacher J, Dinsmore J, Thomas C, Palmer P, Kott S et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat Med 1997; 3: 350-3.
14. 14 Calne RY. Organ transplantation between widely disparate species. Transplant Proc 1970; 2: 550-6.
15. 15 Daar AS. Ethics of xenotransplantation: animal issues, consent, and likely transformation of transplant ethics. World J Surg 1997; 21: 975-82.
16. 16 Davis EA, Pruitt SK, Greene PS, Ibrahim S, Lam TT, Levin JL et al. Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts. Transplantation 1996; 63: 1018-23.
17. 17 Storck M, Abendroth D, Prestel R, Pino-Chavez G, Muller-Hoker J, White DJ et al. Morphology of hDAF (CD55) transgenic pig kidneys following ex-vivo hemoperfusion with human blood. Transplantation 1997; 63: 304-10.
18. 18 Byrne GW, McCurry KR, Martin MJ, McClellan SM, Platt JL, Logan JS. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63: 149-55.
19. 19 Dalmasso AP, Vercelloti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection. Transplantation 1991; 52: 530-3.
20. 20 Kroshus TJ, Bolman RM III, Dalmasso AP, Rollins SA, Guilmette ER, Williams BL et al. Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. Transplantation 1996; 61: 1513-21.
21. 21 White DJ, Cozzi E, Langford G, Oglesby T, Wang MW, Wright L et al. The control of hyperacute rejection by genetic engineering of the donor species. Eye 1995; 9: 185-9.
22. 22 Galili U. Significance of natural human anti-Gal antibody in xenotransplantation. Xenotransplantation 1994; 2: 84-7.
23. 23 Platt JL. The immunological barriers to xenotransplantation. Crit Rev Immunol 1996; 16: 331-58.
24. 24 Platt JL. The prospects for xenotransplantation of the kidney. Curr Opin Nephrol Hypertens 1997; 6: 284-91.
25. 25 Sandrin MS,Fodor WL, Mouhtouris E, Osman N, Cohney S, Rollins SA et al. Enzymatic remodelling of the carbohydrate surface of a xenogeneic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1995; 1: 1261-7.
26. 26 Parker W, Bruno D, Holzknecht ZE, Platt JL. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994; 153: 3791-803.
27. 27 Lin SS, Kooyman DL, Daniels LJ, Daggett CW, Parker W, Lawson JH et al. The role of natural anti-Gal alpha 1-3Gal antibodies in hyperacute rejection of pig-to-baboon cardiac xenotransplants. Transpl Immunol 1997; 5: 212-18.
28. 28 Candinas D, Belliveau S, Koyamada NT, Miyatake T, Hechenleitner P, Mark W et al. T cell independence of macrophage and natural killer cell infiltration, cytokine production, and endothelial activation during delayed xenograft rejection. Transplantation 1996; 62: 1920-7.
29. 29 Robson SC, Kaczmarek E, Siegel JB, Candinas D, Koziak K, Millan M et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997; 185: 153-63.
30. 30 Goodman DJ, Von Albertini M, Willson A, Millan MT, Bach FH. Direct activation of porcine endothelial cells by human natural killer cells. Transplantation 1996; 61: 763-71.
31. 31 Blakely ML, Van der Werf WJ, Berndt MC, Dalmasso AP, Bach FH, Hancock WW. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994; 58: 1059-66.
32. 32 Coughlan AF, Berndt MC, Dunlop LC, Hancock WW. In vivo studies of P-selectin and platelet activating factor during endotoxemia, accelerated allograft rejection, and discordant xenograft rejection. Transplant Proc 1993; 25: 2930-1.
33. 33 Galili U, Tibell A, Samuelsson B, Rydberg L, Groth CG. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. Transplantation 1995; 59: 1549-56.
34. 34 Oriol R, Ye Y, Koren E, Cooper DK. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation. Transplantation 1993; 56: 1433-42.
35. 35 Fishman JA. Miniature swine as organ donors for men: strategies for prevention of xenotransplant associated infections. Xenotransplantation 1994; 1: 47-57.
36. 36 Platt JL. Approaching the clinical application of xenotransplantation. Am J Med Sci 1997; 313: 315-21.
37. 37 Galili U. Evolution and pathophysiology of the human natural anti-alpha Gal antibody. Springer Seminars in Immunopathology 1993; 15: 155-71.
38. 38 Galili U. The natural anti-Gal antibody, the B-like antigen, and human red cell aging. Blood Cells 1988; 14: 205-28.
39. 39 Galili U. The natural anti-Gal antibody: evolution and autoimmunity in man. Immunol Ser 1991; 55: 355-73.
40. 40 Galili U, Clark MR, Shohet SB, Buehler J, Macher B A. Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1-3Gal epitope in primates. Proc Natl Acad Sci USA 1987; 84: 1369-73.
41. 41 Cozzi E, Yannoutsos N, Langford G, Pino-Chavez G, Wallwork J, White D. Effect of transgenic expression of human decay-accelerating factor on the inhibition of hyperacute rejection of pig organs. In: Cooper DK, Kemp E, Platt J, White D, eds. Xenotransplantation the Transplantation of Organs and Tissues Between Species. 2nd ed. Heidelberg: Springer, 1997: 665-82.
42. 42 Koren E, Milotic F, Neethling FA, Koscec M, Fei D, Kobayashi T et al. Monoclonal antiidiotypic antibodies neutralize cytotoxic effects of anti-alphaGal antibodies. Transplantation 1996; 62: 837-43.
43. 43 Platt JL, Lindman BJ, Geller RL, Noreen HJ, Swanson JL, Dalmasso AP et al. The role of natural antibodies in the activation of xenogenic endothelial cells. Transplantation 1991; 52: 1037-43.
44. 44 Platt JL, Vercellotti GM, Lindman BJ, Oegema TR Jr, Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171: 1363-8.
45. 45 Robson SC, Candinas D, Siegel JB, Kopp C, Millan M, Hancock WW et al. Potential mechanism of abnormal thromboregulation in xenograft rejection: loss of ecto-ADPases upon endothelial cell activation. Transplant Proc 1996; 28: 536.
46. 46 Robson SC, Young VK, Cook NS, Metternich R, Kasper-Konig W, Lesnikoski BA et al. Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection. Transplantation 1996; 61: 862-8.
47. 47 Hunt BJ, Rosenberg RD. The essential role of haemostasis in hyperacute rejection. Xenotransplantation 1993; 1: 16-19.
48. 48 Chong AS, Shen J, Xiao F, Blinder L, Wei L, Sankary H et al. Delayed xenograft rejection in the concordant hamster heart into Lewis rat model. Transplantation 1996; 62: 90-6.
49. 49 Matsumiya G, Shirakura R, Miyagawa S, Izutani H, Sawa Y, Nakata S et al. Analysis of rejection mechanism in the rat to mouse cardiac Xenotransplantation. Role and characteristics of anti-endothelial cell antibodies. Transplantation 1994; 57: 1653-60.
50. 50 Candinas D, Bach FH, Hancock WW. Delayed xenograft rejection in complement-depleted T-cell-deficient rat recipients of guinea pig cardiac grafts. Transplant Proc 1996; 28: 678.
51. 51 Hasan R, Van den Bogaerde JB, Wallwork J, White DJ. Evidence that long-term survival of concordant xenografts is achieved by inhibition of antispecies antibody production. Transplantation 1992; 54: 408-13.
52. 52 Cramer DV, Chapman FA, Jaffee BD, Zajac I, Hreha-Eiras G, Yasunaga C et al. The prolongation of concordant hamster-to-rat cardiac xenografts by brequinar sodium. Transplantation 1992; 54: 403-8.
53. 53 Miyazawa H, Murase N, Demetris AJ, Matsumoto K, Nakamura K, Ye Q et al. Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition. Transplantation 1995; 59: 1183-8.
54. 54 Cooper DK, Koren E, Oriol R. Oligosaccharides and discordant transplantation. Immunol Rev 1994; 141: 31-58.
55. 55 Cooper DK, Koren E, Oriol R. Genetically engineered pigs. Lancet 1993; 342: 682-3 (Letter).
56. 56 Cotterell AM, Collins BH, Parker W, Harland RC, Platt JL. The humoral immune response in humans following cross-perfusion of porcine organs. Transplantation 1995; 60: 861-8.
57. 57 Pierson RN III, Winn HJ, Russell PS, Auchincloss HJ Jr. Xenogeneic skin graft rejection is especially dependent on CD4+ T cells. J Exp Med 1989; 170: 991-6.
58. 58 Groth CG. Transplantation of porcine fetal pancreas to diabetic patients. Lancet 1995; 345: 735 (Letter).
59. 59 Wallgren AC, Karlsson-Parra A, Korsgren O. The main infiltrating cell in xenograft rejection is a CD4+ macrophage and not a T lymphocyte. Transplantation 1995; 60: 594-601.
60. 60 Knechtle SJ, Halperin EC, Murphy CE, Saad T, Abernethy K, Miller D et al. The effect of cyclosporine, total lymphoid irradiation, and cobra venom factor on hyperacute rejection. Transplantation 1985; 4: 541-5.
61. 61 Malyguine AM, Saadi S, Platt JL, Dawson JR. Human natural killer cells induce morphologic changes in porcine endothelial cell monolayers. Transplantation 1996; 61: 161-4.
62. 62 Hume DM. Discussion of Reetsma paper. Ann Surg 1964; 160: 409-10.
63. 63 Stevens RB, Wang YL, Kaji H, Lloveras J, Dalmasso A, Bach FH et al. Administration of nonanticoagulant heparin inhibits loss of glycosaminoglycans from xenogeneic cardiac grafts and prolongs graft survival. Transplant Proc 1993; 25: 382.
64. 64 Hancock WW. Beyond hyperacute rejection: strategies for development of pig→primate xenotransplantation. Kidney Int Suppl 1997; 58: S36-40.
65. 65 Hancock WW. Delayed xenograft rejection. World J Surg 1997; 21: 917-23.
66. 66 Kopp CW, Siegel JB, Hancock WW, Anrather J, Winkler H, Geczy CL et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63: 749-58.
67. 67 Bach FH, Ferran C, Hechenleitner P, Mark W, Koyamada N, Miyatake T et al. Accommodation of vascularized xenografts: expression of 'protective genes' by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997; 3: 196-204.
68. 68 Bach FH, Ferran C, Soares M, Wrighton CJ, Anrather J, Winkler H et al. Modification of vascular responses in xenotransplantation: inflammation and apoptosis. Nat Med 1997; 3: 944-8.
69. 69 Ferran C, Badrichani AZ, Cooper JT, Stroka DM, Bach FH. Xenotransplantation: progress toward clinical development. Adv Nepbrol Necker Hosp 1997; 27: 391-420.
70. 70 Ferran C, Stroka DM, Badrichani AZ, Cooper JT, Bach FH. Adenovirus-mediated gene transfer of A20 renders endothelial cells resistant to activation: a means of evaluating the role of endothelial cell activation in xenograft rejection. Transplant Prof 1997; 29: 879-80.
71. 71 Von Albertini M, Ferran C, Brostjan C, Bach FH, Goodman DJ. Membrane-associated lymphotoxin on natural killer cells activates endothelial cells via an NF-kappaB-dependent pathway. Transplantation 1998; 66: 1211-19.
72. 72 Grimm S, Bauer MK, Baeuerle PA, Schulze-Osthoff K. Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis. J Cell Biol 1996; 134: 13-23.
73. 73 Goodman DJ, Von Albertini MA, McShea A, Wrighton CJ, Bach FH. Adenoviral-mediated overexpression of I(kappa)B(alpha) in endothelial cells inhibits natural killer cell-mediated endothelial cell activation. Transplantation 1996; 62: 967-72.
74. 74 Anrather D, Millan MT, Palmetshofer A, Robson SC, Geczy C, Ritchie AJ et al. Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF. J Immunol 1997; 159: 5620-8.
75. 75 Jurd KM, Gibbs RV, Hunt BJ. Activation of human prothrombin by porcine aortic endothelial cells-a potential barrier to pig to human xenotransplantation. Blood Coagul Fibrinolysis 1996; 7: 336-43.
76. 76 Korsgren O. Acute cellular rejection. Xenotransplantation 1997; 4: 11-19.
77. 77 Scheringa M, Buchner B, Geerling RA, de Bruin RW, Schraa EO, Bouwman E et al. Chronic rejection after concordant xenografting. Transplant Proc 1994; 26: 1346-7.
78. 78 Johnsson C, Andersson A, Bersztel A, Karlsson-Parra A, Gannedahl G, Tufveson G. Successful retransplantation of mouse-to-rat cardiac xenografts under immunosuppressive monotherapy with cyclosporine. Transplantation 1997; 63: 652-6.
79. 79 Sawada T, DellaPelle PA, Seebach JD, Sachs DH, Colvin RB, lacomini J. Human cell-mediated rejection of porcine xenografts in an immunodeficient mouse model. Transplantation 1997; 63: 1331-8.
80. 80 Moses RD, Auchincloss HJ. Mechanisms of cellular rejection. In: Cooper DK, Kemp E, Platt J, White D, eds. Xenotransplantation. 2nd ed. Berlin: Springer, 1997: 140-74.
81. 81 Stone KR, Ayala G, Goldstein J, Hurst R, Walgenbach A, Galili U. Porcine cartilage transplants in the cynomolgus monkey. III. Transplantation of alpha-galactosidase-treated porcine cartilage. Transplantation 1998; 65: 1577-83.
82. 82 Palmetshofer A, Galili U, Dalmasso AP, Robson SC, Bach FH. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type II activation. Transplantation 1998; 65: 971-8.
83. 83 Groth CG, Korsgren O, Tibell A, Tollemar J, Moller E, Bounder J et ai. Transplantation of porcine fetal pancreas to diabetic patients. Lancet 1994; 344: 1402-4.
84. 84 Hammer C. Evolutionary considerations in xenotransplantation. In: Hardy MA, ed. Xenograft 25. Amsterdam: Elsevier, 1989: 115-23.
85. 85 Reemtsma K. Heterotransplantation. Transplant Proc 1969; 1: 251-5.
86. 86 Wanke R, Hermanns W, Folger S, Wolf E, Brem G. Accelerated growth and visceral lesions in transgenic mice expressing foreign genes of the growth hormone family: a review. Pediatr Nepbrol 1991; 5: 513-21.
87. 87 Zaidi A, Schmoeckel M, Bhatti F, Waterworth P, Tolan M, Cozzi E et al. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation I998; 65: 1584-90.
88. 88 Groth CG. Xenotransplantation. The viral issue. Lancet 1998; 352(Suppl 4): SIV26.
89. 89 Restifo AC, Ivis-Woodward MA, Tran HM, Nickerson PW, Lehnert AM, Strom TB et al. The potential role for xenogeneic antigen presenting cells in T cell co-stimulation. Xeno 1996; 3: 141-8.
90. 90 Tucker AW, Galbraith D, McEwan P, Onions D. Evaluation of porcine cytomegalovirus as a potential zoonotic agent in xenotransplantation. Transplant Proc 1999; 31: 915.
91. 91 Michaels MG. Infectious concerns of cross-species transplantation: xenozoonoses. World J Surg 1997; 21: 968-74.
92. 92 Michaels MG, Simmons RL. Xenotransplant-associated zoonoses. Strategies for prevention. Transplantation 1994; 57: 1-7.
93. 93 Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997; 3: 282-6.
94. 94 Patience C, Patton G, Takeuchi Y, Weiss RA, Mc Clure M, Ryberg L et al. No evidence of pig DNA or retroviral infection in patients with short-term extra-corporeal connection to pig. Lancet 1998; 352: 699-701.
95. 95 Heneine W, Tibell A, Switzer WM, Sandstrom P, Rosales GV, Mathews A et at. No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet 1998; 352: 695-9(Published erratum appears in Lancet 1998; 352: 1478.)
96. 96 Paradis K, Langford G, Lang Z, Heneine W, Sandstrom P, Switzer WM et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science 1999; 285: 1236-41.
97. 97 McCurry KR, Kooyman DL, Alvarado CG, Cotterell AH, Martin MJ, Logan JS et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995; 1: 423-7.
98. 98 Hansch GM, Hammer CH, Vanguri P, Shin ML. Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci USA 1981; 78: 5118-21.
99. 99 Ish C, Ong GL, Desai N, Mattes MJ. The specificity of alternative complement pathway-mediated lysis of erythrocytes: the survey of complement and target cells in 25 species. Scand J Immunol 1993; 38: 113-22.
100. 100 Langford GA, Cozzi E, Yannoutsos N, Lancaster R, Elsome K, Chen P et al. Production of pigs transgenic for human regulators of complement activation using YAC technology. Transplant Proc 1996; 28: 862-3.
101. 101 Cozzi E, Langford GA, Richards A, Elsome K, Lancaster R, Chen P et al. Expression of human decay accelerating factor in transgenic pigs. Transplant Proc 1994; 26: 1402-3.
102. 102 Cozzi E, Tucker AW, Langford GA, Pino-Chavez G, Wright L, O'Connell MJ et al. Characterization of pigs transgenic for human decay-accelerating factor. Transplantation 1997; 64: 1383-92.
103. 103 Cozzi E, White DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964-6.
104. 104 Schmoeckel AT, Bhatti FN, Zaidi A, Cozzi E, Pino-Chavez G, Dunning JJ et al. Xenotransplantation of pig organs transgenic for human DAF: an update. Transplant Proc 1997; 29:3157-8.
105. 105 Schmoeckel M, Bhatti FN, Zaidi A, Cozzi E, Waterworth PD, Tolan MJ et al. Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation 1998; 65: 1570-7. (Published erratum appears in Transplantation 1998; 66:943.)
106. 106 Schmoeckel M, Kollert G, Shahmohammadi M, Young VK, Chavez G, Kasper-Konig W etal. Prevention of hyperacute rejection by human decay accelerating factor in xenogeneic perfused working hearts. Transplantation 1996; 62: 729-34.
107. 107 Candinas D, Lesnikoski BA, Robson SC, Miyatake T, Scesney SM, Marsh HC Jr et al. Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival. Transplantation 1996; 62: 336-42.
108. 108 Pruitt SK, Bollinger RR, Collins BH, Marsh HC Jr, Levin JL, Rudolph AR el al. Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts. Transplantation 1997; 63:900-2.
109. 109 Zhovv X, Niesen N, Pawlowski I, Biesecker G, Andres G, Brentjens J et al. Prolongation of survival of discordant kidney xenografts by C6 deficiency. Transplantation 1990; 50: 896-8.
110. 110 Pursel VG, Rexroad CE Jr, Bolt DJ, Miller KF, Wall RJ, Hammer RE et al. Progress on gene transfer in farm animals. Vet Immunol Immunopathol 1987; 17: 303-12.
111. 111 Taniguchi S, Neethling FA, Korchagina EY, Bovin N, Ye Y, Kobayashi T et al. In vivo immunoadsorption of antipig antibodies in baboons using a specific Ga1(alpha)1-3Gal column. Transplantation 1996; 62: 1379-84.
112. 112 Lin SS, Weidner BC, Byrne GW, Diamond LE, Lawson JH, Hoopes CW etal. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101: 1745-56.
113. 113 Neethling FA, Koren E, Oriol R, Richards SV, Ye Y, Kujundzic M et al. Immunoadsorption of natural antibodies from human serum by affinity chromatography using specific carbohydrates protects pig cells from cytotoxic destruction. Transplant Proc 1994; 26: 1378.
114. 114 Neethling FA, Koren E, Ye Y, Richards SV, Kujundzic M, Oriol R et al. Protection of pig kidney (PK15) cells from the cytotoxic effect of anti-pig antibodies by alpha-galactosyl oligosaccharides. Transplantation 1994; 57:959-63.
115. 115 Cooper DK, Cairns T, Taube D. Extracorporeal immunoadsorption of anti-Gal antibodies in baboons using alpha-Gal oligosaccharide immunoaffinity columns. Xenotransplantation 1996; 4: 27-9.
116. 116 Soares M, Lu X, Havaux X, Baranski A, Reding R, Latinne D et al. In vivo IgM depletion by anti-mu monoclonal antibody therapy. The role of IgM in hyperacute vascular rejection of discordant xenografts. Transplantation 1994; 57: 1003-9.
117. 117 Yu PB, Holzknecht ZE, Bruno D, Parker W, Platt JL. Modulation of natural IgM binding and complement activation by natural IgG antibodies: a role for IgG anti-Gal alphal-3Gal antibodies. J Immunol 1996; 157: 5163-8.
118. 118 Waterworth PD, Cozzi E, Tolan MJ, Langford G, Braidley P, Chavez G et al. Pig-to-primate cardiac xenotransplantation and cyclophosphamide therapy. Transplant Proc 1997; 29: 899-900.
119. 119 Alexandre GPJ, Gianello P, Latinne D, Carlier M, Dewaele A, Van Obbergh L et al. Plasmapheresis and splenectomy in experimental renal xenotransplantation. In: Hardy MA, ed. Xenograft 25. Amsterdam: Elsevier, 1989: 259-66.
120. 120 Cranston D, Wood KJ, Morris PJ. Splenectomy and renal allograft survival in the rat. Br J Surg 1988; 75: 18-22.
121. 121 Zhong R, Tucker J, Grant D, Wall W, Garcia B, Asfar S et al. Long-term survival and functional tolerance of baboon to monkey kidney and liver transplantation: a preliminary report. Transplant Proc 1996; 28: 762.
122. 122 Cohney S, McKenzie IF, Patton K, Prenzoska J, Ostenreid K, Fodor WL et al. Down-regulation of Gal alpha(1,3) Gal expression by alphal,2-fucosyltransferase: further characterization of alpha 1,2-fucosyItransferase transgenic mice. Transplantation 1997; 64: 495-500.
123. 123 Strahan KM, Gu F, Preece AF, Gustavsson I, Andersson L, Gustafsson K. cDNA sequence and chromosome localization of pig alpha 1,3 galactosyltransferase. Iwmunogenetics 1995; 41: 101-5.
124. 124 Osman N, McKenzie IF, Ostenried K, Ioannou YA, Desnick RJ, Sandrin MS. Combined transgenic expression of alpha-galactosidase and alpha 1,2-fucosyltransferase leads to optimal reduction in the major xenoepitope Galalpha(1,3)Gal. Proc Natl Acad Sci USA 1997; 94: 14677-82.
125. 125 Sandrin MS, Osman N, McKenzie IF. Transgenic approaches for the reduction of Galalpha(1,3)Gal for xenotransplantation. Frontiers in Bioscience 1997; 2: e1-11.
126. 126 McKenzie IF, Osman N, Cohney S, Vaughan HA, Patton K, Mouhtouris E et al. Strategies to overcome the anti-Gal alpha (1-3)Gal reaction in xenotransplantation. Transplant Proc 1996; 28: 537.
127. 127 Tearle RG, Tange MJ, Zannettino ZL, Katerelos M, Shinkel TA, Van Denderen BJ et al. The alpha-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation. Transplantation 1996; 61: 13-19.
128. 128 Miyagawa S, Shirakura R, Taniguchi N, Downregulation of alpha-galactosyl epitope in xenograft. Tanpakushitsu Kakusan Koso 1998; 43(Suppl 16): 2618-24.
129. 129 Sykes M, Lee LA, Sachs DH. Xenograft tolerance, hmminol Rev 1994; 141: 245-76.
130. 130 Parker W, Saadi S, Lin SS, Holzknecht ZE, Bustos M, Platt JL. Transplantation of discordant xenografts: a challenge revisited. Immunol Today 1996; 17: 373-8.
131. 131 Platt JL, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, Najarian JS et al. Transplantation of discordant xenografts: a review of progress.Immunol Today 1990; 11: 450-6.
132. 132 Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168-70.
133. 133 Sachs DH, Sahlinski T. Tolerance against discordant xenogeneic barriers. Xeno 1995; 2: 234-9.
134. 134 Sachs DH, Sykes M, Greenstein J, Cosimi AB. Tolerance and xenograft survival. Nat Med 1995; 1: 969.
135. 135 Wood KJ,The induction of tolerance to alloantigens using MHC class I molecules. Curr Opin Immunol 1993; 5: 759-62.
136. 136 Smit JA, Stark JH, Myburgh JA. Immunologie responses of two monkeys tolerating baboon renal xenografts after total lymphoid irradiation. Transplant Proc 1994; 26: 1063.
137. 137 Zhao Y, Swenson K, Sergio JJ, Arn JS, Sachs DH, Sykes M. Skin graft tolerance across a discordant xenogeneic barrier. Nat Med 1996; 2: 1211-16.
138. 138 Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 1994; 153: 1087-98.
139. 139 Feng S, Quickel RR, Hollister-Lock J, McLeod M, Bonner-Weir S, Mulligan RC et al. Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4Ig. Transplantation 1999; 67: 1607-13.
140. 140 Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991; 114: 954-5.
141. 141 Sayegh MH, Perico N, Gallon L, Imberti O, Hancock WW, Remuzzi G et al. Mechanisms of acquired thymic unresponsiveness to renal allografts. Thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy. Transplantation 1994; 58: 125-32.
142. 142 Perper RJ, Najarian JS. Experimental renal heterotransplantation. I. In widely divergent species. Transplantation 1966; 4: 377-88.
143. 143 Zanjani ED, Srour EF, Hoffman R. Retention of long-term repopulating ability of xenogeneic transplanted purified adult human bone marrow hematopoietic stem cells in sheep. J Lab Clin Med 1995; 126: 24-8.
144. 144 Aksentijevich I, Sachs DH, Sykes M. Humoral tolerance in xenogeneic BMT recipients conditioned by a nonmyeloablative regimen. Transplantation 1992; 53: 1108-14.
145. 145 Starzl TE, Demetris AJ, Murase N, Valdivia L, Thomson AW, FungJ et al. The future of transplantation: with particular reference to chimerism and xenotransplantation. Transplant Proc 1997; 29: 19-27.
146. 146 Khan A, Sergio JJ, Zhao Y, Pearson DA, Sachs DH, Sykes M. Discordant xenogeneic neonatal thymic transplantation can induce donor-specific tolerance. Transplantation 1997; 63: 124-31.
147. 147 Bailey LL, Gundry SR. Evolving status of xenotransplantation: introduction. World J Surg 1997; 21: 899-900.